Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY; ProfiLER investigators. Trédan O, et al. Among authors: desseigne f. Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080. Ann Oncol. 2019. PMID: 30865223 Free article.
[Cardiac metastases and colorectal cancer: a case study].
de la Fouchardière C, Desseigne F, Orlandini F, de la Fouchardière A, Négrier S. de la Fouchardière C, et al. Among authors: desseigne f. Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):621-3. doi: 10.1016/s0399-8320(07)89443-7. Gastroenterol Clin Biol. 2007. PMID: 17646793 Free article. Review. French.
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.
Ray-Coquard I, Dussart S, Goillot C, Mayeur D, Debourdeau P, Ghesquieres H, Bachelot T, Le Cesne A, Anglaret B, Agostini C, Guastalla JP, Lancry L, Biron P, Desseigne F, Blay JY. Ray-Coquard I, et al. Among authors: desseigne f. Ann Oncol. 2009 Jun;20(6):1105-12. doi: 10.1093/annonc/mdn750. Epub 2009 Jan 27. Ann Oncol. 2009. PMID: 19174452 Free article. Clinical Trial.
Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.
de la Fouchardière C, Négrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, Tavan D, Petit-Laurent F, Rivoire M, Pérol D, Carrie C. de la Fouchardière C, et al. Among authors: desseigne f. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):409-13. doi: 10.1016/j.ijrobp.2009.05.008. Epub 2010 Jan 29. Int J Radiat Oncol Biol Phys. 2010. PMID: 20116933 Clinical Trial.
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. Gourgou-Bourgade S, et al. Among authors: desseigne f. J Clin Oncol. 2013 Jan 1;31(1):23-9. doi: 10.1200/JCO.2012.44.4869. Epub 2012 Dec 3. J Clin Oncol. 2013. PMID: 23213101 Clinical Trial.
70 results